Carcinogenesis Advance Access originally published online on November 21, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis, Vol. 25, No. 3, 405-411,
March 2004
Carcinogenesis vol.25 no.3 © Oxford University Press 2004; all rights reserved.
CARCINOGENESIS |
Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression
1 Laboratoire d'Oncogénétique—INSERM E0017, Centre René Huguenin, St-Cloud, France and 2 Laboratoire de Génétique Moléculaire—UPRES EA 3618, Faculté des Sciences Pharmaceutiques et Biologiques, Université René Descartes, Paris V, Paris, France
The PEA3/E1AF/ETV4 gene encodes an Ets-related transcription factor that is expressed in the epithelial cells of the mammary gland. Previous reports have shown that PEA3 can up-regulate promoter activities of many genes associated with tumorigenesis. A significant fraction of those encode matrix metalloproteinases (MMP genes) required for degradation of the extracellular matrix. To better obtain a molecular characterization of PEA3 expression in sporadic breast cancer, we quantified PEA3 mRNA by means of real-time reverse transcriptase–polymerase chain reaction assay in a large series of human primary breast tumors. PEA3 expression showed wide variations in tumor tissues, being under-expressed in 30 of 130 (23.1%) and over-expressed in 18 of 130 (13.8%) compared with normal breast tissues. High PEA3 mRNA levels correlated significantly with Scarff–Bloom–Richardson histopathological grade III (P = 0.018) but not with poor prognosis, suggesting that PEA3 is a marker of tumor aggressiveness rather than a prognostic factor in human breast cancer. We also observed positive links between the expression of PEA3 and those of MKI67 and ERBB2 (P = 0.034 and P = 0.045, respectively) and an inverse relationship with ER
(P = 0.0016). Our results do not support recent findings suggesting that PEA3 could be a tumor-suppressor gene that can act therapeutically in ERBB2 over-expressed tumors. Our results also suggest major roles of the MMP2, NRG1 and CGB genes (which encode type I gelatinase, heregulin and human chorionic gonadotropin ß subunit, respectively) in the PEA3 pathway dysregulation observed in breast cancer. Taken together, the data confirm the role of the PEA3 gene in breast tumorigenesis, and suggest the existence of numerous other still unknown genes transactivated by the PEA3 transcription factor.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. P. Turner, V. J. Findlay, A. D. Kirven, O. Moussa, and D. K. Watson Global Gene Expression Analysis Identifies PDEF Transcriptional Networks Regulating Cell Migration during Cancer Progression Mol. Biol. Cell, September 1, 2008; 19(9): 3745 - 3757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Buteau-Lozano, G. Velasco, M. Cristofari, P. Balaguer, and M. Perrot-Applanat Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer cells through an estrogen receptor-dependent mechanism J. Endocrinol., February 1, 2008; 196(2): 399 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-A. Herve, H. Buteau-Lozano, R. Vassy, I. Bieche, G. Velasco, M. Pla, G. Perret, S. Mourah, and M. Perrot-Applanat Overexpression of Vascular Endothelial Growth Factor 189 in Breast Cancer Cells Leads to Delayed Tumor Uptake with Dilated Intratumoral Vessels Am. J. Pathol., January 1, 2008; 172(1): 167 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Turner, O. Moussa, M. Sauane, P. B. Fisher, and D. K. Watson Prostate-Derived ETS Factor Is a Mediator of Metastatic Potential through the Inhibition of Migration and Invasion in Breast Cancer Cancer Res., February 15, 2007; 67(4): 1618 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Upadhyay, C. Liu, A. Chatterjee, M. O. Hoque, M. S. Kim, J. Engles, W. Westra, B. Trink, E. Ratovitski, and D. Sidransky LKB1/STK11 Suppresses Cyclooxygenase-2 Induction and Cellular Invasion through PEA3 in Lung Cancer Cancer Res., August 15, 2006; 66(16): 7870 - 7879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhu, J. Jiang, H. Shen, H. Wang, H. Zong, Z. Li, Y. Yang, Z. Niu, W. Liu, X. Chen, et al. Elevated {beta}1,4-Galactosyltransferase I in Highly Metastatic Human Lung Cancer Cells: IDENTIFICATION OF E1AF AS IMPORTANT TRANSCRIPTION ACTIVATOR J. Biol. Chem., April 1, 2005; 280(13): 12503 - 12516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Firlej, B. Bocquet, X. Desbiens, Y. de Launoit, and A. Chotteau-Lelievre Pea3 Transcription Factor Cooperates with USF-1 in Regulation of the Murine bax Transcription without Binding to an Ets-binding Site J. Biol. Chem., January 14, 2005; 280(2): 887 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chotteau-Lelievre, F. Revillion, V. Lhotellier, L. Hornez, X. Desbiens, V. Cabaret, Y. de Launoit, and J.-P. Peyrat Prognostic Value of ERM Gene Expression in Human Primary Breast Cancers Clin. Cancer Res., November 1, 2004; 10(21): 7297 - 7303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Davidson, S. Konstantinovsky, S. Nielsen, H. P. Dong, A. Berner, M. Vyberg, and R. Reich Altered Expression of Metastasis-Associated and Regulatory Molecules in Effusions from Breast Cancer Patients: A Novel Model for Tumor Progression Clin. Cancer Res., November 1, 2004; 10(21): 7335 - 7346. [Abstract] [Full Text] [PDF]
|
|